Novo Nordisk A/S vs Verizon Communications Inc — how do they compare? Novo Nordisk A/S trades at $47.23 (market cap $207.85B), while Verizon Communications Inc trades at $46.95 (market cap $196.40B). The key difference: Novo Nordisk A/S and Verizon Communications Inc are close in size by market cap, and Verizon Communications Inc pays the higher dividend (5.99%). Which is the better fit depends on your goals.
| NVO | VZ | |
|---|---|---|
Market Cap | $207.85B | $196.40B |
Sector | Health | Media |
52-Week High | $63.98 | $51.38 |
52-Week Low | $35.29 | $38.40 |
Enterprise Value | $222.55B | $383.10B |
Dividend Yield | 3.81% | 5.99% |
Volume | — | 22,584,735 |
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Verizon (VZ) trades at $46.93, down slightly by 0.21% on the day, with a bullish technical signal from moving averages. The company shows stable fundamentals with $138.19B in 2025 revenue and consistent earnings beats in recent quarters. Recent news highlights network expansion initiatives and strategic partnerships, including a fiber deal with Alphabet. Cash flow improved significantly in 2025 with $14.86B net cash flow, though debt levels remain elevated at $121.38B long-term.
VZ presents a value opportunity with a P/E of 12.31 below sector average and strong dividend yield. Analyst consensus targets $49.69 with 36.7% buy ratings, though competition from SpaceX's Starlink and high debt pose risks. The stock's current price near support at $47 suggests limited downside if technical levels hold.
Trailing returns across standard periods
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →